Position in DNLI
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$2,083
+$528 QoQ
Shares Held
81
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#253
of 290 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Johnson Financial Group, Inc. holds $2,424,373 across 21 Biotechnology names. DNLI ranks #13 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,250 | $2,026,504 | |
| 2 | EXEL |
Exelixis, Inc.
|
3,992 | $217,204 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
134 | $66,561 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
200 | $37,456 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
142 | $34,217 | |
| 6 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
143 | $11,655 | |
| 7 | ABVX |
Abivax S.A.
|
62 | $8,262 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
49 | $4,776 |
All Filings in DNLI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,083 | 81 | Shares | Defined | 2026-08-10 | |
| 2026-03-31 | $1,555 | 81 | Shares | Defined | 2026-05-07 | |
| 2025-12-31 | $1,337 | 81 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $28,677 | 1,975 | Shares | Defined | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||